The Management of Hypertension: A Clinical Dilemma with Health Policy Implications
Analysis of benefit, cost, and efficacy have become increasingly prominent in discussions of health care. As the presentations in this working conference demonstrate, it is always important to preface any discussion with a clear statement of the perspective from which the issue is viewed. Even such purists as economists, health planners, and clinicians may find that their scientific clarity is sometimes distorted by an unappreciated bias. Thus, I would like to state at the outset that my analysis of antihypertensive therapy is from the perspective of the clinician at the point of encounter with the individual patient. While health economists may talk of utility and cost of life years gained with a precision born of detachment, the personal encounter physician enjoys not such luxury. The commitment to his or her patient is absolute. While not unmindful of cost and cost efficacy calculations, the physician at the point of contact is most likely to be influenced by his perception of optimal clinical practice. Furthermore, in that setting, it is my belief that this is exactly what the patient would expect.
KeywordsPlacebo Pneumonia Assure Expense Propranolol
Unable to display preview. Download preview PDF.
- (1).Final report of the subcommittee on definition and prevalence of the 1984 joint national committee. Hypertension prevalence and status of awareness, treatment, and control in the United States. Hypertension 1985; 7: 457–468Google Scholar
- (2).National Center for Health Statistics. Advance report of final mortality statistics, 1985. Monthly vital statistics 1987; 36 (5 suppl): 23Google Scholar
- (3).Weinstein, M.C., Stason, W.B.: Economic consideration in the management of mild hypertension. Ann NY Acad Sci 1978; 424–436Google Scholar
- (7).Alderman, M.H.: The epidemiology of hypertension: etiology, natural history, and the impact of therapy. Cardiovasc. Rev. Rep 1980; 1: 509–519Google Scholar
- (8).Alderman, M.H.: Mild Hypertension: a national approach to clinical management. Einstein Quarterly 1986; 4: 18–20Google Scholar
- (10).McLemore, T., Delozier, J. 1985 summary: national ambulatory medical care survey. Advance data 1987; N128: 1–8Google Scholar
- (13).Schoenberger, J.A.: Benefits and risks of drug therapy in essential hypertension. In: Drayer, J.I. et al. (eds.). Drug Therapy in hypertension. Marcel Dekker, Inc. New York and Basel 1987: 45–56Google Scholar
- (16).A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Untreated mild hypertension. Lancet 1982; 1: 185–191Google Scholar
- (19).Alderman, M.H.: The variation in risk among hypertensive patients. In: Laragh JH et al. (eds.): Frontiers in Hypertension Research. Springer-Verlag, New York, 1981; 11–14Google Scholar
- (22).Alderman, M.H., Stanback, M.E.: Hypertension detection and management through the worksite in the United States. In: Bulpitt, C.J. (ed.); Handbook of Hypertension, Vol. 6: Epidemiology of Hypertension. Elsevier Science Publishers BV; 1985; 373–386Google Scholar
- (24).The HDFP Cooperative Research Group. Mortality findings for stepped-care and referred-care participants in the HDFP, stratified by other risk factors. Rev Med 1985; 14: 312–335Google Scholar